Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

686

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

March 5, 2030

Study Completion Date

July 5, 2032

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Trastuzumab Deruxtecan

T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

DRUG

pembrolizumab

pembrolizumab will be administered at a dose of 200 mg IV Q3W

DRUG

Pemetrexed

Pemetrexed will be administered at a dose of 500 mg/m2 IV Q3W

DRUG

Chemotherapy

"One of the following two will be administered in Arm B:~Cisplatin at a dose of 75 mg/m2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV"

Trial Locations (26)

11590

RECRUITING

Clinical Research Alliance, Westbury

33321

RECRUITING

BRCR Global Plantation, Plantation

77339

RECRUITING

Lumi Research, Kingwood

90027

RECRUITING

California Research Institute, Los Angeles

99508

RECRUITING

Alaska Oncology & Hematology, LLC, Anchorage

Unknown

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

RECRUITING

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Shanghai East Hospital, Shanghai

RECRUITING

Saitama Medical University International Medical Center, Hidaka-shi

RECRUITING

Kansai Medical University Hospital, Hirakata-shi

RECRUITING

Hospital of the University of Occupational and Environmental Health, Kitakyushu-shi

RECRUITING

Saiseikai Kumamoto Hospital, Kumamoto

RECRUITING

Matsusaka Municipal Hospital, Matsusaka-shi

RECRUITING

NHO Kinki-Chuo Chest Medical Center, Sakaishi

RECRUITING

Keijinkai Teine Keijinkai Hospital, Sapporo

RECRUITING

Shizuoka Cancer Center, Sunto-gun

RECRUITING

Wakayama Medical University Hospital, Wakayama

RECRUITING

Kanagawa Cancer Center, Yokohama

RECRUITING

Tottori University Hospital, Yonago-shi

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

Tri-Service General Hospital, Taipei

RECRUITING

Chang Gung Memorial Hospital,Linkou, Taoyuan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT06899126 - Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter